UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine takes on tough breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage study tests a personalized vaccine made from a patient's own tumor, combined with immunotherapy drugs, for triple negative breast cancer. The goal is to see if the vaccine is safe and can help the immune system attack cancer cells. About 18 adults with various st…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 03:32 UTC
-
New hope for tough breast cancer: early trial combines three drugs to fight tumors
Disease control Recruiting nowThis early-stage trial tests a new drug called ASTX727 alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the com…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:33 UTC
-
New triple-drug attack aims to shrink hard-to-treat breast cancer
Disease control Recruiting nowThis early-phase trial tests whether adding an experimental drug (ZEN003694) to standard chemotherapy and immunotherapy is safe for people with advanced triple-negative breast cancer that has spread. About 57 participants will receive the combination to find the best dose and che…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests the safety and best dose of combining two drugs—pidnarulex and trastuzumab deruxtecan—in people with advanced breast cancer or other solid tumors that have a protein called HER2. The study includes up to 36 adults whose cancer has spread, cannot be re…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:24 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC